Our evolving understanding of late kidney allograft failure

Current Opinion in Organ Transplantation

Volumn 16, Issue 6, 2011, Pages 594-599

  Gaston, Robert S ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

antibody mediated rejection; calcineurin inhibitor nephrotoxicity; chronic allograft nephropathy; chronic rejection

Indexed keywords

CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C4D;

GLOMERULUS FILTRATION RATE; GRAFT FAILURE; HLA SYSTEM; HUMAN; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; POLYMERASE CHAIN REACTION; REVIEW;

CALCINEURIN; CYCLOSPORINE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 81255171415     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32834c23a7     Document Type: Review

References (57)

1. Murray JE, Merrill JP, Harrison JH, et al. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med 1963; 268:1315-1323.
2. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11:450-462.
3. United States Renal Data System. USRDS 2008 Annual Data Report. 2008. www.usrds.org. [Accessed 15 October 2008]
4. Matas AJ, Leduc R, Rush D, et al. Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study. Am J Transplant 2010; 10:315-323.
5. Solez K, Colvin RB, Racusen LC, et al. Banff 05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN). Am J Transplant 2007; 7:518-526. (Pubitemid 46376465)
6. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349:2326-2333. (Pubitemid 37509740)
7. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346:580-590. (Pubitemid 34438820)
8. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4:481-508.
9. Hamburger J, Crosnier J, Dormont J, Bach J-F. Renal transplantation: theory and practice. Baltimore: The Williams and Wilkins Co; 1972.
10. Wechter WJ, Brodie JA, Morrell RM, et al. Antithymocyte globulin in renal allograft recipients. Multicenter trials using a 14-dose regimen. Transplantation 1979; 28:294-302. (Pubitemid 10242947)
11. Barber WH, Mankin JA, Laskow DA, et al. Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation 1991; 51:70-75.
12. Wood ML, Gozzo JJ, Monaco AP. Use of antilymphocyte serum and bone marrow for production of immunological tolerance and enhancement: review and recent experiments. Transplant Proc 1972; 4:523-529.
13. Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364:1909-1919.
14. Shapiro R, Jordan ML, Basu A, et al. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg 2003; 238:520-525.
15. WilliamsGM, Lee HM, Weymouth RF, et al. Studies in hyperacute and chronic renal homograft rejection in man. Surgery 1967; 62:204-212.
16. Najarian JS, Fryd DS, Strand M, et al. A single institution, randomized, prospective trial of cyclosporin versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients. Ann Surg 1985; 201:142-157. (Pubitemid 15170079)
17. Starzl TE, Weil R 3rd, Iwatsuki S, et al. The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet 1980; 151:17-26. (Pubitemid 10080547)
18. Calne RY, Thiru S, McMaster P, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978; 2:1323-1327. (Pubitemid 9078430)
19. Myers BD, Ross J, Newton L, et al. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311:699-705. (Pubitemid 14074555)
20. Morris PJ, Allen RD, Thompson JF, et al. Cyclosporin conversion versus conventional immunosuppression: long-term follow-up and histological evaluation. Lancet 1987; 1:586-591. (Pubitemid 17024217)
21. Calne RY, Rolles K, Thiru S, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979; 2:1033-1036. (Pubitemid 10213970)
22. Myers BD, Sibley R, Newton L, et al. The long-term course of cyclosporineassociated chronic nephropathy. Kidney Int 1988; 33:590-600. (Pubitemid 18073785)
23. Elzinga LW, Rosen S, Bennett WM. Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: role of sodium intake. J Am Soc Nephrol 1993; 4:214-221.
24. English J, Evan A, Houghton DC, Bennett WM. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987; 44:135-141.
25. Shihab FS, Bennett WM, Tanner AM, Andoh TF. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997; 52:660-673. (Pubitemid 27402364)
26. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931-940. (Pubitemid 37064766)
27. Simmons RL, Canafax DM, Strand M, et al. Management and prevention of cyclosporine nephrotoxicity after renal transplantation: use of low doses of cyclosporine, azathioprine, and prednisone. Transplant Proc 1985; 17 (4 Suppl 1):266-275. (Pubitemid 16216487)
28. Sollinger HW, Deierhoi M, Kalayoglu M, Belzer FO. Sequential antilymphocyte globulin cyclosporine therapy in cadaver renal transplantation. Transplant Proc 1986; 18 (2 Suppl. 1):16-18. (Pubitemid 16036797)
29. Gallagher MP, Hall B, Craig J, et al. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004; 78:1653-1660. (Pubitemid 39648439)
30. Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18:22-28. (Pubitemid 41742941)
31. Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007; 83:883-892. (Pubitemid 46682728)
32. Van Gurp E, Weimar W, Gaston R, et al. Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am J Transplant 2008; 8:1711-1718.
33. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353:770-781. (Pubitemid 41215486)
34. Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73:775-782. (Pubitemid 34260577)
35. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007; 7:560-570. (Pubitemid 46376436)
36. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575. (Pubitemid 350294223)
37. Flechner SM, Glyda M, Cockfield SM, et al. The ORION Study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11:1633-1644.
38. Kandaswamy R, Humar A, Casingal V, et al. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression. Transplantation 2007; 83:722-726. (Pubitemid 46569189)
39. Vathsala A, Verani R, Schoenberg L, et al. Proteinuria in cyclosporine-treated renal transplant recipients. Transplantation 1990; 49:35-41. (Pubitemid 20051580)
40. Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43:1333-1338. (Pubitemid 23161421)
41. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7:408-415. (Pubitemid 46096334)
42. Mengel M, Reeve J, Bunnag S, et al. Molecular correlates of scarring in kidney transplants: the emergence of mast cell transcripts. Am J Transplant 2009; 9:169-178.
43. Sarwal M, Chua MS, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349:125-138. (Pubitemid 36818782)
44. Cosio FG, Grande JP, Wadei H, et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5:2464-2472.
45. Park WD, Griffin MD, Cornell LD, et al. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010; 21:1987-1997.
46. Mannon RB, Matas AJ, Grande J, et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. Am J Transplant 2010; 10:2066-2073.
47. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90:68-74.
48. Sis B, Jhangri GS, Bunnag S, et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9:2312-2323.
49. Djamali A, Kendziorski C, Brazy PC, Becker BN. Disease progression and outcomes in chronic kidney disease and renal transplantation. Kidney Int 2003; 64:1800-1807. (Pubitemid 37323710)
50. Kasiske BL, Heim-Duthoy KL, Tortorice KL, Rao KV. The variable nature of chronic declines in renal allograft function. Transplantation 1991; 51:330-334.
51. Gaston RS, Leduc R, Schladt D, et al. Late, not early, events have the greatest impact on kidney transplant failure (abstract). Am J Transplant 2011; 11 (Suppl 2):55.
52. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9:527-535.
53. Larsen CP, Grinyo J, Medina-Pestana J, et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010; 90:1528-1535.
54. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10:535-546.
55. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248:564-577.
56. Busque S, Leventhal J, Brennan DC, et al. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant 2009; 9:1936-1945.
57. Webber A, Hirose R, Vincenti F. Novel strategies in immunosuppression: issues in perspective. Transplantation 2011; 91:1057-1064.